Security National Bank Has $760,000 Stock Position in Amgen Inc. (NASDAQ:AMGN)

Security National Bank grew its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 69.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,440 shares of the medical research company's stock after acquiring an additional 1,000 shares during the period. Security National Bank's holdings in Amgen were worth $760,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in AMGN. Pinney & Scofield Inc. bought a new position in shares of Amgen during the fourth quarter worth approximately $26,000. First Pacific Financial increased its holdings in shares of Amgen by 304.5% during the first quarter. First Pacific Financial now owns 89 shares of the medical research company's stock worth $28,000 after purchasing an additional 67 shares during the period. Ritter Daniher Financial Advisory LLC DE increased its holdings in shares of Amgen by 66.2% during the fourth quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock worth $33,000 after purchasing an additional 51 shares during the period. Synergy Investment Management LLC bought a new position in shares of Amgen during the fourth quarter worth approximately $34,000. Finally, Atala Financial Inc bought a new position in shares of Amgen during the fourth quarter worth approximately $34,000. 76.50% of the stock is owned by institutional investors.

Insider Activity at Amgen

In other news, SVP Rachna Khosla sold 1,500 shares of the company's stock in a transaction dated Thursday, June 5th. The shares were sold at an average price of $289.68, for a total transaction of $434,520.00. Following the transaction, the senior vice president now owns 8,162 shares in the company, valued at approximately $2,364,368.16. This represents a 15.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.76% of the stock is owned by company insiders.

Analysts Set New Price Targets

AMGN has been the topic of several recent research reports. Wall Street Zen raised shares of Amgen from a "buy" rating to a "strong-buy" rating in a report on Sunday, May 18th. Guggenheim initiated coverage on shares of Amgen in a research note on Tuesday, May 20th. They issued a "neutral" rating and a $288.00 price objective on the stock. Bank of America lifted their price objective on shares of Amgen from $275.00 to $294.00 and gave the company an "underperform" rating in a research note on Wednesday, March 5th. William Blair reissued an "outperform" rating on shares of Amgen in a research note on Tuesday. Finally, Johnson Rice set a $294.00 price objective on shares of Amgen in a research note on Wednesday, March 5th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $309.22.

Amgen Trading Down 0.7%

Shares of NASDAQ:AMGN traded down $1.98 during mid-day trading on Friday, reaching $277.13. 2,894,198 shares of the company's stock were exchanged, compared to its average volume of 2,833,059. The firm has a market capitalization of $149.02 billion, a price-to-earnings ratio of 25.29, a PEG ratio of 2.52 and a beta of 0.51. The business's fifty day moving average price is $281.02 and its 200-day moving average price is $286.01. The company has a debt-to-equity ratio of 8.70, a quick ratio of 0.88 and a current ratio of 1.17. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical research company reported $4.90 EPS for the quarter, topping analysts' consensus estimates of $4.18 by $0.72. The company had revenue of $8.15 billion for the quarter, compared to analyst estimates of $8.05 billion. Amgen had a net margin of 17.39% and a return on equity of 176.11%. Amgen's revenue was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.96 earnings per share. On average, research analysts predict that Amgen Inc. will post 20.62 EPS for the current fiscal year.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.